Oblimersen
As of the edition of 20 October 2026, Oblimersen is an oligonucleotide: went quiet in 2010; acts on BCL2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2010
- Kind
- Oligonucleotide
- Registered trials
- 1, 0 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| BCL2 | Apoptosis regulator Bcl-2 | P10415 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Genta | Lead sponsor of trials | 2003 to now |